Chronic Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Chronic Pain Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock key insights into the Chronic Pain Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chronic Pain Market Size [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Pain Market Report

* The total 7MM Chronic Pain Prevalent Cases in 2023 US accounted the highest cases.
* Among the EU4 and the UK, the highest number of Chronic Pain prevalent cases were observed in the UK ~ 30%.
* Prevalence of chronic pain increased with age and was higher among those in age group between 45-64 years.
* Approximately 70% of chronic pain cases in the United States in 2023 fall within the category of moderate to severe severity-specific cases.
* The Chronic Pain Companies such as AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH , and others.
* Promising Chronic Pain Therapies such as Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide , and others.

Stay ahead in the competitive landscape of the Chronic Pain Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chronic Pain Treatment Market Size [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Pain Epidemiology Segmentation in the 7MM

* Total Chronic Pain Prevalent Cases
* Total Chronic Pain Diagnosed Cases
* Chronic Pain Severity-specific Cases
* Chronic Pain Age-specific Cases
* Chronic Pain Cause-specific Cases

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Prevalence [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Pain Marketed Drugs

* JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International

JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Improvement of symptoms of osteoarthritis (knee joint and hip joint) is expected by administering JOYCLU into the joint cavity once every 4 weeks. JOYCLU is the first joint function improvement agent in Japan to treat osteoarthritis of the hip joint.

* ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an intra-articular injection to manage osteoarthritis pain in the knee. ZILRETTA is Flexion's novel, proprietary, sustained-release formulation composed of triamcinolone acetonide (TA) embedded in a biodegradable PLGA matrix that extends residence time in the joint for the treatment of mild-to-moderate OA of the knee. ZILRETTA received approval from the FDA on October 2017.

Chronic Pain Emerging Drugs

* ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals.

Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucuronoxylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). GAGs are complex carbohydrates that play a regulatory role in the body through interacting with proteins involved with inflammation. Key features of PPS activity are its anti-inflammatory and tissue regenerative properties, as well as its mild anti-thrombotic activity.

* TNX-102 SL: Tonix Pharmaceuticals

TNX-102 SL, a sublingual tablet with 2.8 mg of cyclobenzaprine HCl, is taken nightly to treat fibromyalgia. Its rapid absorption and reduced production of a long-lasting active metabolite enhance its effectiveness. This patented formulation optimizes cyclobenzaprine delivery to improve sleep quality and minimize residual effects. TNX-102 SL, a centrally-acting analgesic, eases pain by enhancing sleep. It's currently in mid-Phase III development for fibromyalgia management.

Discover the future of Chronic Pain Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Chronic Pain Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Pain Drugs Market

Currently, several types of medications are being used in the management of chronic pain, including acetaminophen, ibuprofen, aspirin, COX-2 inhibitors, antimigraine medications, sedatives, opioids, and antidepressants. Nonpharmacologic treatments for chronic pain can include exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other treatments. There are several approved drugs for the treatment of chronic pain such as EMGALITY (galcanezumab-gnlm), AIMOVIG (erenumab), and AJOVY (fremanezumab), among others.

Chronic Pain Market Outlook

Key Chronic Pain Companies such as Paradigm Biopharmaceuticals, Centrexion Therapeutics, Tonix Pharmaceuticals, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Chronic Pain. According to DelveInsight's analysis, the Chronic Pain Market Growth is expected to be mainly driven by increasing Chronic Pain Prevalence, rise in awareness and access to treatment, alternative options (such as a novel therapeutic agent) to addictive opioids, holistic approach, efforts by the organization and upsurge in the geriatric population.

Explore the dynamics of the Chronic Pain Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chronic Pain Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/chronic-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Pain Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Chronic Pain Companies- AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH , and others.
* Chronic Pain Therapies- Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others.
* Chronic Pain Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Chronic Pain Unmet Needs, KOL's views, Analyst's views, Chronic Pain Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Chronic Pain Market Overview at a Glance

4 Executive Summary of Chronic Pain

5 Key events

6 Disease Background and Overview

7 Epidemiology and Patient Population

8 Patient Journey

9 Marketed Products

10 Emerging Therapies

11 Chronic Pain: The Seven Major Markets Analysis

12 SWOT Analysis

13 Unmet Needs

14 KOL Views

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pain-therapeutics-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2034-estimates-delveinsight]
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.